Adagene Presents Data Demonstrating the Best-in-Class Therap

- MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with a confirmed partial response at ADG126 10 mg/kg every three weeks plus pembrolizumab – - Integrated...

Related Keywords

Suzhou , Jiangsu , China , Singapore , San Diego , California , United States , Japan , Australia , , Nasdaq , Exchange Commission , European Union , Society For Immunotherapy Of Cancer , Linkedin , Twitter , Dynamic Precision Library , Adagene Inc , Safebody Technology , Annual Meeting , Optimal Dose Selection , Significantly Widened Therapeutic Index Compared , Media Contact , Markets ,